Outcome Measures in Duchenne Muscular Dystrophy: A Natural History Study

Duchenne Muscular Dystrophy Clinical Trial

Official title:

Developing Tools for Assessing the Natural History of Ambulant and Non-ambulant DMD Individuals to Assist in Antisense-oligomer Clinical Trials

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02780492
• Other study ID #: 12/0096 (09DN17)
• Status: Completed
• Start date: April 11, 2012
• Est. completion date: April 28, 2022

Study information

• Verified date: January 2024
• Source: University College, London
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Novel emerging therapies for Duchenne Muscular Dystrophy (DMD) require a deeper understanding of DMD natural history. This study aim to assess the natural history of DMD through a composite assessment tool capable of capturing disease progression linking ambulant and non-ambulant phases of the disease.

Description:

Novel emerging therapies for Duchenne Muscular Dystrophy (DMD) require a deeper understanding of DMD natural history. This study aim to assess the natural history of DMD through a composite assessment tool capable of capturing disease progression linking ambulant and non-ambulant phases of the disease. With a recruitment target of 80 DMD patients across 5 centres (London, Newcastle, Paris, Leiden, Nijmegen), subjects are assessed 6 monthly according to a shared protocol. Assessments include 6-minute walk distance (6MWD), North Star Ambulatory Assessment (NSAA), Performance of Upper Limb (PUL) and MyoSet (myogrip, myopinch and moviplate). Both ambulant and non-ambulant subjects undergo upper limb evaluation and respiratory function test including forced vital capacity (FVC), maximum inspiratory and expiratory pressures (MIP/MEP). A subgroup of patients performs annual whole body DEXA scan. An imaging sub-study will aim to characterize muscle (upper/lower limb) and brain MRI. The investigators will analyze the longitudinal data for the different assessment tools and explore correlations among them. This study will offer a comprehensive natural history of DMD including novel outcome measures, allowing to capture disease progression and explore the relationship between different assessment tools.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: April 28, 2022
• Est. primary completion date: April 28, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 5 Years to 18 Years

Eligibility

Inclusion Criteria:

For non-ambulant patients:

1. Children and teenagers aged between 5 and 18 years with DMD, who have lost the ability to walk 10 meters with no support

2. The diagnosis of DMD must be documented by genetic testing. If a muscle biopsy is available, it should contain less than 10% of revertant fibres

3. Patients should have deletions amenable of skipping of exons 51 or 53 or 45 or 44 or 46 or 50 or 52

4. Patients should be capable of sitting upright in a wheelchair for at least an hour

5. Patients should be stable from a respiratory point of view. Artificial ventilation with either Bipap or tracheostomy is not a contraindication to the study.

6. Informed consent signed by a parent/legal guardian (or by the patient if 16 years of age).

7. In France, a subject will be eligible for inclusion in this study only if either affiliated to, or a beneficiary of, a social security category.

For ambulant patients:

1. Ambulant children from 5 years old and teenagers with DMD, and potential candidates for future genetic therapies with antisense oligomer (AO) exon skipping

2. The diagnosis of DMD must be documented by MLPA or a standard genetic test for the disorder, genotypically confirmed to have an out-of-frame deletion(s) that could be corrected by skipping exon 51 or 53 or 45 or 44 or 46 or 50 or 52

3. If a muscle biopsy is available less than 10% revertant fibres

4. Ability to walk independently for at least 75 meters in 6 minutes at recruitment.

5. Patients should receive the standard of care for DMD as recommended by the NorthStar UK and TREAT-NMD (i.e.: on glucocorticoids treatment)

6. Sufficiently preserved pulmonary function (FVC >30%) and absence of symptoms of cardiac failure

7. Informed consent signed by a parent/legal guardian (or by the patient if 16 years of age)

8. In France, a subject will be eligible for inclusion in this study only if either affiliated to, or a beneficiary of, a social security category.

For healthy volunteers and disease controls:

1. Participant are able to provide informed consent/assent for taking blood samples and/or performing limb MRI and/or physiotherapy assessment of the upper limb function

2. Participants have a neuromuscular disease that is not Duchenne Muscular Dystrophy or are a healthy volunteer with no neuromuscular disease

3. Able to have a blood sample taken Exclusion Criteria:

For non-ambulant patients:

1. Patients who are currently involved in interventional clinical trials aimed at restoring dystrophin will be excluded, as their data could not be used to establish natural history of the disease (participation in a previous interventional clinical trial prior to 6 months from being recruited in the study is not an exclusion criterion)

2. Patients with severe intellectual impairment, who would be unable to cooperate with examination

3. Patients/families the investigators anticipate may have emotional/ psychological problems if recruited into a natural history study

4. Symptomatic cardiac failure

5. Recent (< 6 months) upper limb surgery or trauma

6. Anticipated surgery for anytime during the duration of the study

7. None of the current treatments for DMD are exclusion criteria

8. For the MRI sub-study, patients with metal/metallic surgically inserted equipment incompatible with MRI scan will be excluded as well as patients suffering from claustrophobia.

For ambulant patients:

1. Patients who are currently involved in interventional clinical trials aimed at restoring dystrophin will be excluded, as their data could not be used to establish natural history of the disease (participation in a previous interventional clinical trial prior to 6 months from being recruited in the study is not an exclusion criterion)

2. Patients with severe intellectual impairment, who would be unable to cooperate with examination

3. Patients/families the investigators anticipate may have emotional/ psychological problems if recruited into a natural history study

4. Recent surgery or anticipated for anytime during the duration of the study

5. For the MRI sub-study, patients with metal/metallic surgically inserted equipment incompatible with MRI scan will be excluded as well as patients suffering from claustrophobia. For healthy volunteers and disease controls

1. Patients who are currently involved in interventional clinical trials aimed at restoring dystrophin will be excluded, as their data could not be used to establish natural history of the disease (participation in a previous interventional clinical trial prior to 6 months from being recruited in the study is not an exclusion criterion)

2. Patients with severe intellectual impairment, who would be unable to cooperate with examination

3. Patients/families the investigators anticipate may have emotional/ psychological problems if recruited into a natural history study

4. For the MRI sub-study, patients with metal/metallic surgically inserted equipment incompatible with MRI scan will be excluded as well as patients suffering from claustrophobia

Related Conditions & MeSH terms

• Duchenne Muscular Dystrophy
• Muscular Dystrophies
• Muscular Dystrophy, Duchenne

Intervention

Other:
• Set of assessment tools

Locations

Country	Name	City	State
France	Institut de Myologie, Groupe Hospitalier Pitié Salpêtrière	Paris
Netherlands	Leiden University Medical Centre	Leiden
Netherlands	Radboud University Medical Centre	Nijmegen
United Kingdom	Dubowitz Neuromuscular Centre, UCL-Institute of Child Health	London
United Kingdom	John Walton Muscular Dystrophy Research Centre, Newcastle University	Newcastle

Sponsors (6)

Lead Sponsor	Collaborator
University College, London	Association Française contre les Myopathies (AFM), Paris, Groupe Hospitalier Pitie-Salpetriere, Leiden University Medical Center, Radboud University Medical Center, University of Newcastle Upon-Tyne

Countries where clinical trial is conducted

France,  Netherlands,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease progression	Evaluate disease progression from ambulant to non-ambulant patients through a composite assessment tool	up to 4 years